TriSalus Life Sciences and the University of Texas today announced a collaboration to evaluate the treatment of solid tumors.
The Texas MD Anderson Cancer Center and TriSalus will collaborate on treatments for tumors of the pancreas and liver by integrating interventional delivery of SD-101, an investigational toll-like receptor 9 (TLR9) agonist, in combination with checkpoint inhibition immunotherapy, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.